Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2025 Feb 26

PMID 40011325

Authors

Xiaolin Zhu

Chien-Kuang C Ding

Rahul R Aggarwal

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Treatment-emergent neuroendocrine prostate cancer (NEPC) is aggressive and lethal. As androgen receptor signaling inhibitors (ARSIs) are increasingly used in earlier disease settings, treatment-emergent NEPC becomes more prevalent, and effective therapies are urgently needed. The purpose of this review was to summarize recent progress on emerging therapeutic targets of NEPC.

Recent Findings: A multitude of therapeutic targets have emerged in NEPC over recent years. These targets may represent drivers of treatment-emergent lineage plasticity or simply be overexpressed on the surface of NEPC cells. Multiple modalities have been employed to drug these targets, with promising preclinical and clinical results. Treatment-emergent NEPC represents a distinct and clinically significant subset of castration-resistant prostate cancer (CRPC). Emerging therapeutic approaches have demonstrated encouraging efficacy and safety profiles, offering the potential to improve patient outcomes.

References

Yamada Y, Beltran H . Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep. 2021; 23(2):15. PMC: 7990389. DOI: 10.1007/s11912-020-01003-9. View

Eule C, Hu J, Al-Saad S, Collier K, Boland P, Lewis A . Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clin Genitourin Cancer. 2023; 21(4):483-490. PMC: 10536803. DOI: 10.1016/j.clgc.2023.04.008. View

Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G . Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24):2492-2503. PMC: 6366813. DOI: 10.1200/JCO.2017.77.6880. View

Quintanal-Villalonga A, Chan J, Yu H, Peer D, Sawyers C, Sen T . Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020; 17(6):360-371. PMC: 7397755. DOI: 10.1038/s41571-020-0340-z. View

Sequist L, Waltman B, Dias-Santagata D, Digumarthy S, Turke A, Fidias P . Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3(75):75ra26. PMC: 3132801. DOI: 10.1126/scitranslmed.3002003. View

Rubin M, Bristow R, Thienger P, Dive C, Imielinski M . Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Mol Cell. 2020; 80(4):562-577. PMC: 8399907. DOI: 10.1016/j.molcel.2020.10.033. View

Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A . The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023; 83(16):2763-2774. PMC: 10425725. DOI: 10.1158/0008-5472.CAN-23-0593. View

Ku S, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich Z . Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017; 355(6320):78-83. PMC: 5367887. DOI: 10.1126/science.aah4199. View

Mu P, Zhang Z, Benelli M, Karthaus W, Hoover E, Chen C . SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017; 355(6320):84-88. PMC: 5247742. DOI: 10.1126/science.aah4307. View

10.

Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y . Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov. 2017; 7(7):736-749. PMC: 5501744. DOI: 10.1158/2159-8290.CD-16-1174. View

11.

Park J, Lee J, Sheu K, Wang L, Balanis N, Nguyen K . Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018; 362(6410):91-95. PMC: 6414229. DOI: 10.1126/science.aat5749. View

12.

Aparicio A, Shen L, Tapia E, Lu J, Chen H, Zhang J . Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res. 2015; 22(6):1520-30. PMC: 4794379. DOI: 10.1158/1078-0432.CCR-15-1259. View

13.

Corn P, Heath E, Zurita A, Ramesh N, Xiao L, Sei E . Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019; 20(10):1432-1443. PMC: 6858999. DOI: 10.1016/S1470-2045(19)30408-5. View

14.

Cyrta J, Augspach A, Filippo M, Prandi D, Thienger P, Benelli M . Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat Commun. 2020; 11(1):5549. PMC: 7642293. DOI: 10.1038/s41467-020-19328-1. View

15.

Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R . Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2021; 601(7893):434-439. PMC: 8770127. DOI: 10.1038/s41586-021-04246-z. View

16.

Adams E, Karthaus W, Hoover E, Liu D, Gruet A, Zhang Z . FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019; 571(7765):408-412. PMC: 6661172. DOI: 10.1038/s41586-019-1318-9. View

17.

Baca S, Takeda D, Seo J, Hwang J, Ku S, Arafeh R . Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021; 12(1):1979. PMC: 8010057. DOI: 10.1038/s41467-021-22139-7. View

18.

Han M, Li F, Zhang Y, Dai P, He J, Li Y . FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022; 40(11):1306-1323.e8. DOI: 10.1016/j.ccell.2022.10.011. View

19.

Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T . ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 2022; 13(1):2282. PMC: 9046280. DOI: 10.1038/s41467-022-29963-5. View

20.

Chen C, Tran W, Song K, Sugimoto T, Obusan M, Wang L . Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell. 2023; 41(12):2066-2082.e9. PMC: 10878415. DOI: 10.1016/j.ccell.2023.10.009. View